tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Revolution Medicines Receives FDA Voucher for Daraxonrasib
PremiumCompany AnnouncementsRevolution Medicines Receives FDA Voucher for Daraxonrasib
1d ago
Promising Prospects for Revolution Medicines: Buy Rating Affirmed on Daraxonrasib’s CNPV Designation
Premium
Ratings
Promising Prospects for Revolution Medicines: Buy Rating Affirmed on Daraxonrasib’s CNPV Designation
2d ago
Revolution Medicines awarded voucher for Daraxonrasib by FDA
Premium
The Fly
Revolution Medicines awarded voucher for Daraxonrasib by FDA
2d ago
Revolution Medicines: Strategic Positioning and Promising Phase 3 Trials Drive Buy Rating
PremiumRatingsRevolution Medicines: Strategic Positioning and Promising Phase 3 Trials Drive Buy Rating
19d ago
Revolution Medicines price target raised to $71 from $70 at JPMorgan
Premium
The Fly
Revolution Medicines price target raised to $71 from $70 at JPMorgan
23d ago
These 2 Stocks Could Be Prime Takeover Targets, According to Analysts
Premium
Stock Analysis & Ideas
These 2 Stocks Could Be Prime Takeover Targets, According to Analysts
24d ago
Promising Position of Revolution Medicines’ Zoldonrasib Justifies Buy Rating
PremiumRatingsPromising Position of Revolution Medicines’ Zoldonrasib Justifies Buy Rating
1M ago
Revolution Medicines price target raised to $70 from $67 at Wells Fargo
Premium
The Fly
Revolution Medicines price target raised to $70 from $67 at Wells Fargo
1M ago
Promising Potential of Daraxonrasib in Pancreatic Cancer Boosts Buy Rating for Revolution Medicines
Premium
Ratings
Promising Potential of Daraxonrasib in Pancreatic Cancer Boosts Buy Rating for Revolution Medicines
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100